

HOTLINE: Effective August 15, 2022

3000231 *Blastomyces dermatitidis* Antibodies by **Immunoassay** with Reflex to **BLST R CSF**
Immunodiffusion, CSF

Methodology: Semi-Quantitative Enzyme-Linked Immunosorbent **Assay/Immunodiffusion**

Reference Interval:

Effective August 15, 2022

0.9 IV or less	Negative
1.0-1.4 IV	Equivocal
1.5 IV or greater	Positive

Interpretive Data:

Refer to **report**.

Note: This immunoassay detects total antibodies against yeast-phase antigens from *Blastomyces dermatitidis*.

If *Blastomyces* antibodies are equivocal or positive by immunoassay then *Blastomyces dermatitidis* Antibodies by Immunodiffusion will be added. Additional charges apply.

HOTLINE NOTE: There is a clinically significant charting name change associated with this test.

Change the charting name for component 3000233, Blastomyces Antibody by EIA, CSF from Blastomyces Antibody by EIA, CSF to **Blastomyces Antibodies EIA, CSF**.